Altimmune ALT
NASDAQ ALT
$3.34 +0.11 (+3.25%)
As of: Sep 4, 2026 · 1:34 PM EDT

Altimmune (ALT) EV to CFO (2017 - 2026)

Analysis

Altimmune (ALT) EV to CFO (2017 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.27 Bn 131.42 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.55 Bn 77.56 Bn 3.93 Bn
3 Argenx Se 63.45 Bn 58.27 Bn 1.37 Bn
4 Moderna 57.73 Bn 52.59 Bn 52.00 Mn
5 Revolution Medicines 44.08 Bn 44.08 Bn -
6 BeOne Medicines 39.95 Bn 34.85 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.14 Bn 31.84 Bn 992.69 Mn
8 Royalty Pharma 28.44 Bn 27.60 Bn -
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn
10 Altimmune 616.60 Mn 616.60 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -10.94
Mar 31, 2026 -3.32
Dec 31, 2025 -2.29
Sep 30, 2025 -12.57
Jun 30, 2025 -7.55
Mar 31, 2025 -14.21
Dec 31, 2024 -21.34
Sep 30, 2024 -10.96
Jun 30, 2024 -16.98
Mar 31, 2024 -32.99
Dec 31, 2023 -24.26
Sep 30, 2023 0.17
Jun 30, 2023 -1.34
Mar 31, 2023 -2.18
Dec 31, 2022 -36.08
Sep 30, 2022 -28.30
Jun 30, 2022 -21.42
Mar 31, 2022 -6.15
Dec 31, 2021 -8.43
Sep 30, 2021 -14.02